Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study
about
Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term safety and efficacy ...... week open-label, phase 3 study
@en
Long-term safety and efficacy ...... eek open-label, phase 3 study.
@nl
type
label
Long-term safety and efficacy ...... week open-label, phase 3 study
@en
Long-term safety and efficacy ...... eek open-label, phase 3 study.
@nl
prefLabel
Long-term safety and efficacy ...... week open-label, phase 3 study
@en
Long-term safety and efficacy ...... eek open-label, phase 3 study.
@nl
P2093
P2860
P356
P1476
Long-term safety and efficacy ...... week open-label, phase 3 study
@en
P2093
Hiroki Sano
Kohei Kaku
Shingo Kuroda
Yoshifumi Seki
P2860
P304
P356
10.1111/JDI.12499
P577
2016-03-28T00:00:00Z